Vanda Pharmaceuticals (VNDA) Financials

Vanda Pharmaceuticals (NASDAQ: VNDA) showed a mixed but still cash-rich financial profile in the latest quarter, with revenue holding relatively steady while profitability remained deeply negative. The company continues to generate meaningful gross profit, but operating expenses are still high enough to keep it unprofitable on a quarterly basis.

Key takeaways from the last four years:

• VNDA still has a substantial liquidity cushion, with $202.3 million in cash and short-term investments at the end of Q1 2026, giving it room to fund operations near term.
• Gross profit remains strong: Q1 2026 revenue of $51.7 million produced $48.6 million in gross profit, showing the core business still has attractive product economics.
• The company’s balance sheet remains solvent, with $280.8 million in equity versus $152.8 million in liabilities in Q1 2026.
• Over the past several quarters, VNDA has continued to produce positive investing cash flow at times from maturing and selling investments, helping offset operating losses.
• Revenue has been fairly stable over the period, generally ranging from the high-$40 million to high-$50 million range per quarter, suggesting a relatively steady commercial base.
• Share count has not shown dramatic dilution recently, with weighted average basic shares staying roughly in the 58 million to 60 million range.
• Non-operating income has been a recurring benefit, but it has not been enough to offset the company’s operating losses.
• VNDA’s balance sheet includes meaningful intangible assets and deferred tax assets, which are important but also make the asset base less liquid than cash alone.
• The biggest issue remains profitability: Q1 2026 net loss was $48.6 million, and the company also posted a $50.2 million operating loss.
• Operating cash flow was negative in Q1 2026 at -$50.2 million, continuing a long pattern of cash burn from operations.
• Operating expenses remain heavy, with SG&A of $68.4 million and R&D of $28.4 million in Q1 2026, far above gross profit.
• There is a clear year-over-year deterioration in liquidity: cash and short-term investments fell from about $335.7 million in Q1 2025 to $202.3 million in Q1 2026.
• Retained earnings remain deeply negative at -$443.3 million, reflecting years of cumulative losses.

Looking back over the last four years, the trend is consistent: VNDA has maintained a commercially viable revenue stream, but expenses have stayed high enough that the company has not reached sustained profitability. In 2024 and 2025, quarterly revenue stayed relatively stable, while operating losses widened in some periods, especially when SG&A climbed sharply.

One notable positive is that VNDA still has a healthy balance sheet relative to its size, with significant cash and investment holdings. That reduces immediate financing risk. However, the persistent operating losses and negative operating cash flow mean investors should continue to watch the pace of cash usage closely. If losses do not improve, the company’s cash position could keep shrinking over time.

In short, VNDA looks financially stable for now, but not yet fundamentally profitable. The stock’s longer-term story will likely depend on whether management can narrow operating losses while preserving revenue and gross margin.